|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AOX1 |
Gene summary for AOX1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AOX1 | Gene ID | 316 |
| Gene name | aldehyde oxidase 1 | |
| Gene Alias | AO | |
| Cytomap | 2q33.1 | |
| Gene Type | protein-coding | GO ID | GO:0006805 | UniProtAcc | Q06278 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 316 | AOX1 | NAFLD1 | Human | Liver | NAFLD | 3.68e-13 | 1.35e+00 | -0.04 |
| 316 | AOX1 | S41 | Human | Liver | Cirrhotic | 1.80e-02 | 5.46e-01 | -0.0343 |
| 316 | AOX1 | S43 | Human | Liver | Cirrhotic | 5.26e-06 | -7.65e-02 | -0.0187 |
| 316 | AOX1 | S44 | Human | Liver | HCC | 4.47e-06 | 8.89e-01 | -0.0083 |
| 316 | AOX1 | HCC1_Meng | Human | Liver | HCC | 3.80e-62 | -1.81e-01 | 0.0246 |
| 316 | AOX1 | HCC2_Meng | Human | Liver | HCC | 1.05e-09 | -3.48e-01 | 0.0107 |
| 316 | AOX1 | cirrhotic1 | Human | Liver | Cirrhotic | 1.83e-06 | -3.36e-01 | 0.0202 |
| 316 | AOX1 | cirrhotic2 | Human | Liver | Cirrhotic | 3.21e-07 | -3.44e-01 | 0.0201 |
| 316 | AOX1 | HCC1 | Human | Liver | HCC | 2.72e-25 | 5.86e+00 | 0.5336 |
| 316 | AOX1 | HCC5 | Human | Liver | HCC | 3.82e-03 | 3.98e+00 | 0.4932 |
| 316 | AOX1 | Pt13.a | Human | Liver | HCC | 8.36e-03 | -2.37e-01 | 0.021 |
| 316 | AOX1 | Pt13.b | Human | Liver | HCC | 1.05e-07 | -2.10e-01 | 0.0251 |
| 316 | AOX1 | Pt14.d | Human | Liver | HCC | 1.73e-03 | -2.14e-01 | 0.0143 |
| 316 | AOX1 | S028 | Human | Liver | HCC | 4.14e-08 | 6.90e-01 | 0.2503 |
| 316 | AOX1 | S029 | Human | Liver | HCC | 2.84e-12 | 9.54e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00094107 | Liver | NAFLD | response to xenobiotic stimulus | 88/1882 | 462/18723 | 2.53e-09 | 4.11e-07 | 88 |
| GO:00714663 | Liver | NAFLD | cellular response to xenobiotic stimulus | 33/1882 | 177/18723 | 3.54e-04 | 5.36e-03 | 33 |
| GO:00068054 | Liver | NAFLD | xenobiotic metabolic process | 22/1882 | 111/18723 | 1.42e-03 | 1.58e-02 | 22 |
| GO:000941012 | Liver | Cirrhotic | response to xenobiotic stimulus | 165/4634 | 462/18723 | 6.82e-08 | 2.09e-06 | 165 |
| GO:00714661 | Liver | Cirrhotic | cellular response to xenobiotic stimulus | 66/4634 | 177/18723 | 1.34e-04 | 1.31e-03 | 66 |
| GO:000680511 | Liver | Cirrhotic | xenobiotic metabolic process | 43/4634 | 111/18723 | 7.51e-04 | 5.54e-03 | 43 |
| GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
| GO:00714662 | Liver | HCC | cellular response to xenobiotic stimulus | 93/7958 | 177/18723 | 4.35e-03 | 1.89e-02 | 93 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa002806 | Liver | NAFLD | Valine, leucine and isoleucine degradation | 20/1043 | 48/8465 | 3.03e-07 | 1.65e-05 | 1.33e-05 | 20 |
| hsa0028011 | Liver | NAFLD | Valine, leucine and isoleucine degradation | 20/1043 | 48/8465 | 3.03e-07 | 1.65e-05 | 1.33e-05 | 20 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AOX1 | SNV | Missense_Mutation | c.869G>C | p.Arg290Thr | p.R290T | Q06278 | protein_coding | tolerated(0.32) | benign(0.155) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response | |
| AOX1 | SNV | Missense_Mutation | c.523G>C | p.Glu175Gln | p.E175Q | Q06278 | protein_coding | tolerated(0.25) | benign(0.131) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| AOX1 | SNV | Missense_Mutation | c.2299N>G | p.Gln767Glu | p.Q767E | Q06278 | protein_coding | tolerated(0.16) | benign(0.027) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| AOX1 | SNV | Missense_Mutation | c.1534N>C | p.Val512Leu | p.V512L | Q06278 | protein_coding | deleterious(0.01) | benign(0.314) | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| AOX1 | SNV | Missense_Mutation | c.3272N>A | p.Val1091Glu | p.V1091E | Q06278 | protein_coding | deleterious(0) | benign(0.348) | TCGA-AN-A0XS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| AOX1 | SNV | Missense_Mutation | c.3062N>T | p.Arg1021Leu | p.R1021L | Q06278 | protein_coding | tolerated(0.43) | benign(0.003) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| AOX1 | SNV | Missense_Mutation | novel | c.3065N>A | p.Ala1022Asp | p.A1022D | Q06278 | protein_coding | deleterious(0.02) | benign(0.281) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| AOX1 | SNV | Missense_Mutation | c.173N>T | p.Arg58Leu | p.R58L | Q06278 | protein_coding | deleterious(0) | benign(0.336) | TCGA-E9-A1NH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| AOX1 | SNV | Missense_Mutation | rs777167805 | c.206N>C | p.His69Pro | p.H69P | Q06278 | protein_coding | deleterious(0.02) | benign(0.047) | TCGA-E9-A1RG-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| AOX1 | SNV | Missense_Mutation | rs777167805 | c.206A>C | p.His69Pro | p.H69P | Q06278 | protein_coding | deleterious(0.02) | benign(0.047) | TCGA-EW-A1J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 316 | AOX1 | DRUGGABLE GENOME | Menadione | MENADIONE | ||
| 316 | AOX1 | DRUGGABLE GENOME | azathioprine | AZATHIOPRINE | 19500084 | |
| 316 | AOX1 | DRUGGABLE GENOME | febuxostat | FEBUXOSTAT | 27798726 | |
| 316 | AOX1 | DRUGGABLE GENOME | allopurinol | ALLOPURINOL | 27798726 | |
| 316 | AOX1 | DRUGGABLE GENOME | XK469 | |||
| 316 | AOX1 | DRUGGABLE GENOME | Isovanillin | ISOVANILLIN |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |